Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.12 USD | +2.17% | -1.00% | -19.85% |
05-30 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
05-30 | Bristol Myers: FDA approval for Breyanzi | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company is in debt and has limited leeway for investment
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.85% | 81.59B | B | ||
+40.73% | 734B | C+ | ||
+32.83% | 591B | B | ||
-6.30% | 350B | C+ | ||
+15.15% | 315B | B- | ||
+4.05% | 276B | C+ | ||
+15.00% | 238B | B+ | ||
+9.78% | 206B | B- | ||
-5.52% | 204B | A+ | ||
+6.17% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BMY Stock
- Ratings Bristol-Myers Squibb Company